# Job Description

# NIHR Academic Clinical Fellowship

# Clinical or Medical Oncology - ST1 entry

# (1 single speciality post)

Hull York Medical School, in partnership with Health Education England Yorkshire and the Hull University Teaching Hospitals NHS Trust, has developed an exciting pathway of academic clinical training opportunities.

Applications are now invited for an Academic Clinical Fellowship in **Clinical or Medical** **Oncology** at **ST1** level. *There will be 1 ACF post in either Medical Oncology or Clinical Oncology.* This post is funded and approved by the National Institute for Health Research in the **Platform Science and Bioinformatics** theme and offers candidates a comprehensive experience of clinical academic medicine working alongside internationally renowned clinicians and researchers.

We are seeking a highly motivated, enthusiastic individual with the potential to excel in both their clinical and academic training and who has the ambition to be the next generation of academic clinicians.

This Academic Clinical Fellowship (ACF) programme in Oncology is run by Hull York Medical School (HYMS) in conjunction with the Hull University Teaching Hospitals NHS Trust and Health Education England Yorkshire and the Humber.

Academic Clinical Fellowships (ACFs) are 3 year fixed-term national training posts. Trainees undertake 75% clinical and 25% academic training over the term of the post. They are employed by the NHS Trust and have an honorary contract with the University at whose Medical School their academic research is supported.

ACF trainees also undertake a Research Training Programme provided by the University. They are eligible for a training bursary up to £1,000 per year to support research training activity (e.g. to attend academic conferences).

ACF trainees would also normally complete and submit an external funding application for a research fellowship to enable them to complete a higher degree (PhD or research MD) following the completion of their ACF fixed-term post, which would be completed as Out-of-Programme-Research (OOPR).

All Academic Clinical Fellowships are run-through posts, regardless of specialty, with the exception of ‘Medical Education’ ACFs. A trainee entering ACF at ST1 or ST2 in a specialty with a Core Training period would therefore be guaranteed continued training to CCT in the eventual specialty, as long as they progress satisfactorily through both their academic and clinical training. Run-through status is withdrawn if ACFs do not complete the academic component.

# POST DETAILS

## Job Title

NIHR Academic Clinical Fellow (ACF) – Oncology

## Duration of the Post

Up to 3 years (25% academic, 75% clinical).

## Lead NHS Hospital/Trust in which training will take place

Hull University Teaching Hospitals NHS Trust (see details of rotation below).

## Research institution in which training will take place

The successful candidate will be based at the Centre of Biomedicine (in the new £28 million Allam Research Building, Hull York Medical School and University of Hull), and with our NHS partner – Hull University Teaching Hospitals NHS Trust (Castle Hill Hospital site, based in the Queen’s Centre, Castle Hill Hospital, Hull). The Fellow will be supervised by Professor Anthony Maraveyas (Professor and Consultant in Oncology, Hull York Medical School and Hull University Teaching Hospitals NHS Trust) and Dr Leonid Nikitenko (Lecturer in Biomedical Sciences, Hull York Medical School, Faculty of Health Sciences, University of Hull).

## Research Protected Time:

ACFs have protected time to attend and complete either an MSc by research or take relevant modules to extend their training (if they already have an MSc), at Hull York Medical School, if deemed apropriate. The protected research period (25% time) is used to obtain specific experience and knowledge in the research area of interest, obtain pilot data, and apply for an external research fellowship.

## Academic Clinical Fellowship Training Programme: Research Component

This ACF post is funded by NIHR under the Platform Science and Bioinformatics theme.

This proposed Oncology ACF has the opportunity to research molecular pathways in PDAC (pancreatic ductal adenocarcinoma) in the Platform Science theme, using platform techniques such as:

1. next generation-sequencing, including single cell RNA sequencing (scRNAseq);

2. high throughput and confocal imaging/microscopy;

3. bio(medical)informatics analysis using the University of Hull’s High Performance Computer (HPC) VIPER

These currently active strands within the research group will readily underpin a PhD Fellowship application on: (i) early PDAC changes during carcinogenesis, e.g. epithelial to mesenchymal transition, or (ii) molecular mechanisms of PDAC perineural invasion; the second being a particularly novel concept, where the group is currently studying the role of cellular signalling via G-protein coupled receptors.

There is substantial scope in micro-dissecting neuro-lymphatic-cancer/malignant cell crosstalk using these platform technologies, especially using scRNAseq and high throughput and confocal imaging/microscopy. Full training in research methods and relevant techniques will be provided. The ACF will gain experience in human cell and cancer biology research, transcriptomics and bio(medical)informatics analysis through this and the wider body of work of the research group, and supported to present their research in national and international conferences.

There is urgent need to improve early diagnosis and treatment of pancreatic cancer, which is closely linked to low socio-economic status and poor environs prevalent in Hull. The Cancer Research Group promotes translational research to tackle one of the highest incidences and poorest mortality rates from cancer nationally. It has pioneered development of a Global Data, Platform Science and Bioinformatics theme in Hull, using the state-of-the-art infrastructure of HPC VIPER and next generation sequencing equipment. This will provide the ACF with an immersive experience in human cell and cancer biology research, including national collaborations (e.g. Wellcome Trust Centre for Human Genetics, University of Oxford, and Cancer Institute, University College London).

Please contact Prof Anthony Maraveyas for further details (anthony.maraveyas@nhs.net )

Full training in research methods and good clinical practice will be provided. On appointment, in conjunction with their supervisors, the ACF will complete a Training Needs Analysis (TNA) and be able to access modules from the HYMS Post Graduate Training Selection list both to help with their research project and with their professional development as a researcher.

We anticipate the successful exit point for ACF trainees will be the award of an externally funded clinical research training fellowship to pursue a PhD or MD; prior to re-joining the academic career path as a Clinical Lecturer.

## Academic Clinical Fellowship Training Programme: Clinical Component

ST1 entrants will undertake their core medical training in Yorkshire and the Humber (North and East rotation). This is an excellent training area, with a fantastic mix of world leading hospitals, a forward-thinking training programme, with years of experience of incorporating simulation, and a well-developed trainee engagement programme. Significant investment in PACES preparation has led to continuous year-on-year improvement in MRCP (UK) pass rates. Further details of the training programme are available at

<https://heeyh-deanery-live.azurewebsites.net/medicine/core_medical_training>

They will subsequently join the Yorkshire and Humber Oncology training rotation (East), and rotate through posts in tertiary and district general hospitals to gain a wide range of haematology experience. Comprehensive training in Medical or Clinical Oncology is provided throughout.

Further details are available at

[www.yorksandhumberdeanery.nhs.uk/medicine/haematology/home](http://www.yorksandhumberdeanery.nhs.uk/medicine/haematology/home)

## Academic Leads and Supervisors:

Prof Anthony Maraveyas

Professor and Consultant in Oncology at Hull York Medical School

anthony.maraveyas@nhs.net

Dr Leonid Nikitenko

Lecturer in Biomedical Sciences at Hull York Medical School

l.nikitenko@hull.ac.uk

## Clinical Training Programme Directors

Dr Sathish Kallankara

Training Programme Director for Internal Medicine

sathish.kallankara@nhs.net

Dr Dan Lee

Training Programme Director for Medical Oncology

daniel.lee4@nhs.net

Dr Katy Clarke

Training Programme Director for Clinical Oncology

katy.clarke@nhs.net

## Academic Training Programme Director

Professor Bob Phillips

Academic Training Programme Director

Hull York Medical School

bob.phillips@york.ac.uk

# Further Information

Because of the nature of the work for which you are applying, this post is exempted from the provisions of Section 4 (2) of the Rehabilitation of Offenders Act 1974 by virtue of the Rehabilitation of Offenders Act 1974 (Exceptions) Order 1975.

Applicants are therefore, not entitled to withhold information about convictions, which for other purposes are “spent” under the provisions of the Act, and in the event of employment any failure to disclose such convictions could result in dismissal or disciplinary action by the University. Any information given will be strictly confidential and will be considered only in relation to an application for positions to which the Order applies.

For further information about the Academic Clinical Fellowship programme, please refer to the NIHR (National Institute for Health Research) Trainee Coordinating Centre (NIHRTCC) page on [NIHR Integrated Academic Training For Doctors and Dentists - Academic Clinical Fellowships](https://www.nihr.ac.uk/funding-and-support/funding-for-training-and-career-development/training-programmes/integrated-academic-training-programme/integrated-academic-training/academic-clinical-fellowships/)

# Appendix 1: Further particulars – Hull York Medical School

Hull York Medical School is committed to transforming the health of people within the region and beyond – through its students, staff and the impact of its teaching and research.

The joint medical school of the Universities of Hull and York, Hull York Medical School has a reputation as one of the UKs most exciting, contemporary schools. The School was established in 2003 – combining York’s strength in biological sciences and health sciences and Hull’s expertise in clinically applied health research and large clinical base. Since then, has been inspiring doctors and academic leaders of the future with the research, skills and knowledge they need to look at things differently and advance improvements in healthcare around the world.

Equality, diversity and inclusion are extremely important to the School, and in line with its values of everyone counts, pursuing excellence, socially responsible and collaborative, it is committed to providing an inclusive and supportive environment for staff and students. The School was awarded the Athena Swann Silver Award in 2019, has signed up to the UK Medical School’s Charter on So-Called ‘Conversion Therapy’ and the British Medical Association (BMA) racial harassment charter.

**Inspiring doctors and academic leaders of the future**

Hull York Medical School offers exceptional medical education delivered by senior academics and clinicians in a stimulating and supportive environment with world-class facilities.

Postgraduate research students benefit from a thriving research community and the opportunity to learn from world leading experts who are internationally recognised for their work.

Hull York Medical School facilities at Hull and York offer a stimulating environment in which to learn. The Allam Medical Building at the heart of the University of Hull’s £28million Health Campus is home to Hull York Medical School in Hull. Opened in 2017 by Her Majesty the Queen, the Allam Medical Building provides specialised teaching facilities including a simulated ward, operating theatre and intensive care nursing facilities, and provides opportunities for medical students to work alongside, nursing, midwifery and allied health undergraduates, as well as PhD students, advanced nurse practitioners and physician’s associates.

**A partnership for people who want to make a difference**

Academic and clinical researchers at Hull York Medical School have a strong reputation for their work. Their research is advancing improvements in healthcare – treatment, diagnosis and care – for some of the major global health challenges of today. At Hull, the School’s researchers are at the forefront of health research, from the early diagnosis of cancer, to reducing inequalities in access to treatment and improving the lives of those with life-limiting illnesses. This work is improving the health of people locally and impacting national and international health agendas. At York, the School’s researchers have a global reputation for their work. From scientific discoveries that underpin the development, diagnosis and treatment of the world’s most aggressive diseases, to mental health research which addresses the needs of a wider variety of patients and helps to identify, treat and support them, this work is casting new light and impacting public health globally.